Sectoral Asset Management Inc Sage Therapeutics, Inc. Transaction History

Sectoral Asset Management Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 13, 2020	SELL	$41.13 - $62.45 $320,814 - $487,110	-7,800 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$25.95 - $43.15 $202,410 - $336,570	7,800 New	7,800 $324,000
Q1 2020 May 13, 2020	SELL	$26.15 - $77.24 $200,047 - $590,886	-7,650 Closed	0 $0
Q4 2019 Feb 12, 2020	SELL	$60.18 - $154.77 $171,513 - $441,094	-2,850 Reduced 27.14%	7,650 $552,000
Q3 2019 Nov 14, 2019	SELL	$140.29 - $189.96 $1.95 Million - $2.64 Million	-13,900 Reduced 56.97%	10,500 $1.47 Million
Q2 2019 Aug 14, 2019	SELL	$157.85 - $183.09 $1.14 Million - $1.32 Million	-7,200 Reduced 22.78%	24,400 $4.47 Million
Q1 2019 May 14, 2019	SELL	$89.33 - $163.65 $491,315 - $900,075	-5,500 Reduced 14.82%	31,600 $5.03 Million
Q2 2018 Aug 13, 2018	BUY	$140.36 - $175.76 $631,620 - $790,920	4,500 Added 13.8%	37,100 $5.81 Million
Q1 2018 May 15, 2018	BUY	$152.15 - $192.33 $2.34 Million - $2.96 Million	15,400 Added 89.53%	32,600 $5.25 Million
Q4 2017 Feb 13, 2018	BUY	$60.72 - $167.34 $1.04 Million - $2.88 Million	17,200	17,200 $2.83 Million

217

48.2M

854K

195K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $428M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Sectoral Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Sectoral Asset Management Inc with notifications on news.